From Hospital AI to Home Monitoring: Taiwan's Health-Tech Sector Tests Its U.S. Market Fit in Dallas
DALLAS, Oct. 13, 2026 /PRNewswire/ -- Taiwan's healthcare technology sector has no shortage of devices, AI models or clinical data. The harder question is what happens when those technologies leave Taiwan: whether they can validate across different patient populations, clear U.S. regulatory requirements, fit American clinical workflows and find partners capable of deploying and servicing them locally.
That challenge was at the center of the Smart Healthcare Pavilion at Taiwan Expo USA 2026, organized by the International Trade Administration (TITA), Ministry of Economic Affairs (MOEA), and implemented by the Taiwan External Trade Development Council (TAITRA) as reported live on-site by GeneOnline. The Expo was held September 24–26 at the Kay Bailey Hutchison Convention Center Dallas.
Ten Taiwanese hospitals and health-tech companies brought technologies spanning chronic-disease management, hospital AI, remote monitoring, elder care, medical computing and rehabilitation, but they arrived at markedly different stages of U.S. expansion. Some were looking for their first American clinical or commercial partners; others already had FDA-cleared or listed products, U.S. customers, pilots or operations on the ground.
TAITRA Chairman James C. F. Huang placed that effort within the Expo's wider push toward U.S.–Taiwan industrial collaboration. "Texas stands as Taiwan's premier U.S. investment hub, and Dallas is where we lay deep, shared foundations," Huang said at the opening. "This is co-innovation in action."
For healthcare, that co-innovation has practical requirements. A Taiwanese AI model may need American clinical data; a monitoring device may need FDA clearance; a care platform may require local installation and service; and even an established product still has to solve a problem important enough for hospitals to change existing workflows. The ten exhibitors in Dallas offered a cross-section of how Taiwan's health-tech sector is approaching those barriers — and how its traditional strengths in hardware and manufacturing are increasingly being combined with software, clinical data and technologies developed inside hospitals.
Health Technology: Turning the Months Between Doctor Visits Into Usable Data
For H2 Inc., also known as Health2Sync, the problem begins between appointments. Patients with diabetes and other chronic conditions can generate months of glucose, blood-pressure, weight, diet and exercise data while physicians may have only minutes to assess their condition during a visit. "Most people with chronic diseases go back and see doctors once every two to three months," said Erin Chung, Vice President of Business Development at Health2Sync.
The company's platform combines a patient application with a cloud-based system for healthcare providers, aggregating information from connected devices while using AI to interpret some of the behavioral data generated at home. Its meal-analysis function, for example, can analyze food photographs and help users connect dietary choices with changes in glucose. The aim is not to replace the physician visit but to make the period between visits more visible, giving patients information they can act on while providing clinicians with a more organized longitudinal picture.
Health2Sync remains relatively early in its U.S. expansion and used Dallas to explore relationships with primary-care providers, clinics, accountable care organizations, software platforms and payers. Its experience in Taiwan is central to that proposition. "When it comes to technology, Taiwan is always known for hardware," Chung said. "But when we talk about the healthcare industry, specifically digital health, I think that Taiwan provides a perfect environment for product development and innovation."
That point extended beyond Health2Sync. Taiwan's digitized healthcare environment gives companies an opportunity to develop products alongside healthcare providers and clinical data, but the U.S. question is whether those models can translate into a substantially different reimbursement and delivery system.
Smart Hospitals: Taking AI Beyond the Institutions That Developed It
For Taichung Veterans General Hospital (TCVGH) and Chang Gung Memorial Hospital, the challenge is different. Neither is a conventional technology vendor. Their systems emerged from problems encountered directly in clinical practice, making international validation and commercial partnerships critical if those technologies are to move beyond the hospitals that developed them.
At TCVGH, AI development has become an institution-wide strategy. "In my hospital, the policy is that we should ask every department to have at least one AI project," said Deputy Superintendent Yuan-Hwa Chou, MD, PhD, noting that the hospital has 55 departments. That approach has produced applications spanning emergency care, urine analysis, sleep-related conditions and other specialties.
One system presented in Dallas uses contactless facial analysis to help assess pain and identify potentially acute illness in the emergency department. Its relevance is operational: high-volume emergency departments must continuously determine which patients require attention first, while clinicians cannot manually observe everyone at all times. TCVGH reported 86% specificity in recent data for identifying acute critical illness and is seeking further validation across different healthcare settings.
That next step exposes a central issue for hospital-developed AI. A model developed around Taiwanese patients and workflows cannot simply be assumed to perform identically in another population or healthcare system. As a public hospital, TCVGH can develop and clinically evaluate technologies, but bringing them beyond the institution requires external partners. "We have to collaborate with the company," Chou said.
Chang Gung Memorial Hospital faces a similar validation question with an AI system for HER2 FISH assessment in breast cancer. Conventional assessment requires pathologists to manually examine a limited selection of cells, while Chang Gung's approach analyzes cells across a broader slide area to better account for tumor heterogeneity. The technology has been developed predominantly using Taiwanese data, with additional Japanese cases.
"Our data currently only use the Taiwanese data, and some part of it we use Japanese, but it's also Asian," the Chang Gung team said. "We lack American and European data, so we also seek collaboration."
Chih-Che Donti Lin, MD, PhD, Vice Superintendent and Professor of Surgery, described the hospital's direction around both validation in American populations and partnerships capable of moving hospital-developed technologies toward the U.S. market. The HER2 technology has patent protection in Taiwan, while its U.S. patent process is underway. Chang Gung also used its Dallas presence to discuss advanced surgical capabilities and international medical collaboration, making its U.S. strategy as much about connecting hospitals, specialists and patient populations as exporting an individual technology.
Together, TCVGH and Chang Gung illustrate a distinctive part of Taiwan's health-tech pipeline: hospitals are not simply end users of technology but sources of it. Their difficulty comes later, when a clinically useful system needs broader datasets, regulatory pathways and commercial partners to move outside the environment where it was created.
Smart Care: Extending Monitoring When Staff Cannot Be Everywhere
Workforce pressure connected the four companies in the pavilion's Smart Care segment. Their technologies differed, but each addressed a variation of the same constraint: hospitals and care facilities cannot continuously increase staffing as the amount of patient information requiring attention grows.
Onyx Healthcare Inc. approached the problem through medical computing and workflow. Unlike several exhibitors still establishing their U.S. strategy, the company already has a substantial American presence. "We have actually been in the U.S. for ten years, so it's been a while," said Carol Tiernan of Onyx Healthcare USA.
Its Dallas portfolio included the Venus mobile nursing workstation, which combines computing, swappable batteries and configurable peripherals in a mobile system. The value lies less in any single hardware component than in reducing the number of separate systems nurses must navigate while delivering care. "We make medical AI practical and deployable," Tiernan said. "We help hospitals improve workflow efficiency, reduce staff load and deliver safe patient care."
Onyx also presented Casper AI, a contactless monitoring system that uses sensors around the patient environment to track movement, restlessness, bed exits and other indicators. Those signals can be converted into risk information for nursing teams without requiring another wearable on the patient. With Onyx equipment already present in U.S. hospitals, including VA facilities, Dallas was about expanding an existing footprint rather than testing whether a U.S. market exists.
VitalSigns Technology Co., Ltd. addresses the same staffing constraint after the patient leaves a continuously monitored environment. "Cardiac risk is always happening with or without you watching," said CEO Rich Lee. "That is the key problem we are solving."
Patients in intensive-care and telemetry beds have access to continuous cardiac monitoring, but someone discharged after treatment may remain at cardiovascular risk without the same infrastructure. VitalSigns' device received U.S. FDA clearance in 2025, and the company said its first American rollout is underway in Texas through a local partner. It is now pursuing another U.S. clearance for its software platform while developing post-discharge and hospital-at-home applications.
"At home, you need something," Lee said. "We are filling that gap right now.
